Children’s Cancer Research Fund – 2025 Hard-to-Treat Award
The CCRF Hard-to-Treat Award supports innovative research focused on pediatric cancers with a 5-year survival rate below 70%, relapsed/metastatic behavior, or specific high-risk molecular subtypes. Projects may include pilot studies, feasibility studies, secondary data analyses, methodology development, and technology innovation.
Eligibility Criteria
-
U.S.-based nonprofit research institutions
-
PI-eligible applicants from U.S. institutions (U.S. citizenship not required)
-
Open to new and previously unfunded NIH R03/R21 proposals
-
Only one application per PI per calendar year
-
Must commit at least 10% research effort annually to the project
Funding Details
-
Total amount: up to $125,000/year
-
Duration: Up to 2 years (total of $250,000 max)
-
Indirect costs: Up to 10% of direct costs allowed
-
Allowable costs: salaries, fringe benefits, supplies, equipment, travel, sub-contracts
Key Deadlines
-
Full Application Deadline: July 9, 2025 (12:00 p.m. CT)
-
Award Notifications: Rolling (pending fund availability)
-
Earliest Start Date: January 2026
-
Latest Start Date: June 2026
Award Obligations
-
Submit progress reports at 6, 12, and 24 months
-
Follow NIH salary cap and reporting requirements
-
Adhere to data sharing plans following FAIR principles
-
Cannot use funds for embryonic stem cells or fetal tissue research
-
No-cost extensions allowed with request 2 months prior to project end
Further Information
Website: childrenscancer.org/awards
Email: [email protected]
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023